Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Recommendation of “Buy” from Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have been assigned an average rating of “Buy” from the eleven research firms that are covering the firm, Marketbeat reports. Ten equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $57.10.

MIRM has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $66.00 target price on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Robert W. Baird upped their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Leerink Partners upped their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Finally, Citigroup upped their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th.

Mirum Pharmaceuticals Trading Up 0.9 %

Shares of NASDAQ MIRM opened at $48.88 on Monday. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The stock has a market capitalization of $2.35 billion, a P/E ratio of -24.20 and a beta of 0.98. Mirum Pharmaceuticals has a 1-year low of $23.14 and a 1-year high of $50.00. The business has a fifty day moving average price of $44.31 and a 200 day moving average price of $41.92.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The firm had revenue of $90.38 million during the quarter, compared to analysts’ expectations of $81.99 million. During the same period in the prior year, the business posted ($0.57) EPS. The firm’s quarterly revenue was up 89.4% on a year-over-year basis. Equities research analysts expect that Mirum Pharmaceuticals will post -1.44 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Christopher Peetz sold 6,837 shares of the firm’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $47.92, for a total transaction of $327,629.04. Following the sale, the chief executive officer now directly owns 125,022 shares of the company’s stock, valued at $5,991,054.24. This trade represents a 5.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Peter Radovich sold 1,998 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $85,554.36. Following the sale, the chief operating officer now directly owns 27,015 shares in the company, valued at approximately $1,156,782.30. This trade represents a 6.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,622 shares of company stock valued at $1,398,791 over the last ninety days. Company insiders own 22.87% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Rhumbline Advisers boosted its position in Mirum Pharmaceuticals by 2.4% during the fourth quarter. Rhumbline Advisers now owns 53,113 shares of the company’s stock worth $2,196,000 after purchasing an additional 1,236 shares in the last quarter. Legato Capital Management LLC boosted its position in Mirum Pharmaceuticals by 7.9% during the fourth quarter. Legato Capital Management LLC now owns 13,395 shares of the company’s stock worth $554,000 after purchasing an additional 977 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in Mirum Pharmaceuticals during the fourth quarter worth approximately $413,000. Empowered Funds LLC purchased a new position in Mirum Pharmaceuticals during the fourth quarter worth approximately $1,376,000. Finally, Golden State Equity Partners lifted its position in shares of Mirum Pharmaceuticals by 1,390.8% in the fourth quarter. Golden State Equity Partners now owns 19,380 shares of the company’s stock valued at $801,000 after acquiring an additional 18,080 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.